GNA Biosciences

GNA Biosolutions is a molecular diagnostics company that has pioneered Pulse Controlled Amplification (PCA), a transformative technology for rapid nucleic acid testing. Based in Martinsried, Germany, the company developed a platform that utilizes microcyclers to perform ultra-fast thermal cycling, enabling PCR-quality results in minutes. Their technology is designed to work directly from complex clinical samples, such as whole blood or sputum, without the need for time-consuming sample preparation. GNA's product portfolio includes the Pharos VPE system and assays for critical pathogens like MRSA and SARS-CoV-2. In 2019, the company was acquired by Luminex Corporation to integrate its rapid molecular capabilities into Luminex's point-of-care diagnostic suite.